Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 87; no. 3; p. 1002
• Main Authors: Cindi, Zinhle, Maartens, Gary, Bradford, Yuki, Venter, Willem D F, Sokhela, Simiso, Chandiwana, Nomathemba C, Haas, David W, Sinxadi, Phumla
• Format: Journal Article
• Language: English
• Published: United States 01.07.2021
• Subjects: Adult; Anti-HIV Agents - administration & dosage; Anti-HIV Agents - therapeutic use; Drug Therapy, Combination; Female; Genome-Wide Association Study; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - therapeutic use; HIV Infections - drug therapy; HIV-1; Humans; Male; Oxazines - administration & dosage; Oxazines - therapeutic use; Piperazines - administration & dosage; Piperazines - therapeutic use; Polymorphism, Genetic; Prodrugs; Pyridones - administration & dosage; Pyridones - therapeutic use; South Africa; Tenofovir - administration & dosage; Tenofovir - therapeutic use; Weight Gain - drug effects; Weight Gain - genetics; South Africa

Excessive weight gain affects some HIV-positive individuals prescribed dolutegravir-containing regimens. Mechanisms underlying such weight gain are unknown. Data and DNA from antiretroviral therapy-naïve participants who were randomized to initiate dolutegravir with emtricitabine plus either tenofov...